Literature DB >> 25389350

Idiopathic pulmonary fibrosis with emphysema: evidence of synergy among emphysema and idiopathic pulmonary fibrosis in smokers.

Patrick D Mitchell1, Jeeban P Das2, David J Murphy2, Michael P Keane3, Seamas C Donnelly3, Jonathan D Dodd2, Marcus W Butler3.   

Abstract

BACKGROUND: Emphysema and fibrosis, typically the idiopathic pulmonary fibrosis (IPF) form of usual interstitial pneumonia (UIP), can co-exist as combined pulmonary fibrosis emphysema (CPFE). It is unknown whether there is a pathobiologic basis for CPFE beyond the coexistence of fibrosis and emphysema. The aim of this study was to ascertain radiologic differences in severity of fibrosis and emphysema in smokers with IPF versus other forms of UIP.
METHODS: Computed tomography thorax images were prospectively rescored in retrospectively identified smokers (minimum 5-pack-year history) with radiologic UIP (any etiology). Radiologic severity (emphysema/fibrosis/reticulation) was scored in consensus by two radiologists, blinded to clinical details, across 5 lung regional levels, and then correlated with clinical data.
RESULTS: For the whole cohort (IPF, n=102; non-IPF UIP [mainly rheumatoid arthritis/asbestosis/scleroderma], n=30), IPF and non-IPF UIP smokers were similar regarding pack-year, age, gender, and lung function (P>.1). IPF smokers had greater whole lung fibrosis and reticulation scores (P<.04 in all cases). CPFE was present in n=61 (IPF, n=49; non-IPF UIP, n=12). Compared with smokers with non-IPF CPFE, smokers with IPF and emphysema (IPFE) were similar regarding confounders (P>.1). There were significantly greater regional reticulation severity (P=.009), cumulative emphysema severity (P=.04), and cumulative reticulation severity (P<.001) scores in IPFE versus non-IPF CPFE.
CONCLUSIONS: When controlled for confounders, smokers with IPFE have worse radiologic CPFE than other smokers with non-IPF UIP and emphysema, suggesting an interactive synergy among IPF, emphysema, and smoking, with more extensive emphysema due to either inherent susceptibility and/or traction effects. IPFE should be considered separately from other CPFE in future work. It is currently unknown whether CPFE is a distinct pathobiologic entity; therefore, we identified subjects with radiologic UIP (any etiology) who had been similarly exposed to smoke, and asked whether there are differences in the extent/severity of radiologic fibrosis and/or emphysema in those with IPF versus individuals with non-IPF UIP. Although relevant confounders were similar, IPF smokers had greater whole lung fibrosis and reticulation scores than smokers with secondary forms of UIP, and in the CPFE subgroup, smokers with IPF/emphysema had worse radiologic CPFE findings than smokers with non-IPF UIP/emphysema. It is shown for the first time that relevant confounding variables do not explain the observed excess radiologic severity of emphysema and fibrosis in smokers with IPF compared with smokers with non-IPF UIP, lending support to the hypothesis that there is a pathobiologic mechanism or synergy involved in IPF with emphysema that is distinct from the mere co-existence of UIP and emphysematous processes.
Copyright © 2015 by Daedalus Enterprises.

Entities:  

Keywords:  connective tissue disease; emphysema; idiopathic pulmonary fibrosis; reticulation score; smoking; usual interstitial pneumonia

Mesh:

Year:  2014        PMID: 25389350     DOI: 10.4187/respcare.03389

Source DB:  PubMed          Journal:  Respir Care        ISSN: 0020-1324            Impact factor:   2.258


  7 in total

1.  p53 and miR-34a Feedback Promotes Lung Epithelial Injury and Pulmonary Fibrosis.

Authors:  Shwetha K Shetty; Nivedita Tiwari; Amarnath S Marudamuthu; Bijesh Puthusseri; Yashodhar P Bhandary; Jian Fu; Jeffrey Levin; Steven Idell; Sreerama Shetty
Journal:  Am J Pathol       Date:  2017-03-06       Impact factor: 4.307

2.  Serial automated quantitative CT analysis in idiopathic pulmonary fibrosis: functional correlations and comparison with changes in visual CT scores.

Authors:  Joseph Jacob; Brian J Bartholmai; Srinivasan Rajagopalan; Maria Kokosi; Ryoko Egashira; Anne Laure Brun; Arjun Nair; Simon L F Walsh; Ronald Karwoski; Athol U Wells
Journal:  Eur Radiol       Date:  2017-09-29       Impact factor: 5.315

3.  DSP rs2076295 variants influence nintedanib and pirfenidone outcomes in idiopathic pulmonary fibrosis: a pilot study.

Authors:  Martina Doubkova; Eva Kriegova; Simona Littnerova; Petra Schneiderova; Martina Sterclova; Vladimir Bartos; Martina Plackova; Monika Zurkova; Radka Bittenglova; Vladimira Lostaková; Lenka Siskova; Pavlina Lisa; Hana Suldova; Michael Doubek; Jana Psikalova; Tomas Snizek; Pavlina Musilova; Martina Vasakova
Journal:  Ther Adv Respir Dis       Date:  2021 Jan-Dec       Impact factor: 4.031

4.  Increased monocyte count as a cellular biomarker for poor outcomes in fibrotic diseases: a retrospective, multicentre cohort study.

Authors:  Madeleine K D Scott; Katie Quinn; Qin Li; Robert Carroll; Hayley Warsinske; Francesco Vallania; Shirley Chen; Mary A Carns; Kathleen Aren; Jiehuan Sun; Kimberly Koloms; Jungwha Lee; Jessika Baral; Jonathan Kropski; Hongyu Zhao; Erica Herzog; Fernando J Martinez; Bethany B Moore; Monique Hinchcliff; Joshua Denny; Naftali Kaminski; Jose D Herazo-Maya; Nigam H Shah; Purvesh Khatri
Journal:  Lancet Respir Med       Date:  2019-03-29       Impact factor: 102.642

Review 5.  Treating Pulmonary Fibrosis with Non-Viral Gene Therapy: From Bench to Bedside.

Authors:  Teng Huang; Jia Gao; Long Cai; Hao Xie; Yuhan Wang; Yi Wang; Qing Zhou
Journal:  Pharmaceutics       Date:  2022-04-07       Impact factor: 6.525

6.  Use of machine learning models to predict prognosis of combined pulmonary fibrosis and emphysema in a Chinese population.

Authors:  Qing Liu; Di Sun; Yu Wang; Pengfei Li; Tianci Jiang; Lingling Dai; Mengjie Duo; Ruhao Wu; Zhe Cheng
Journal:  BMC Pulm Med       Date:  2022-08-29       Impact factor: 3.320

7.  Combined Pulmonary Fibrosis Emphysema: Role of Cigarette Smoking and Pulmonary Hypertension in a Rural Cohort.

Authors:  Rahul Sangani; Andrew Ghio; Stacey Culp; Zalak Patel; Sunil Sharma
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2021-06-21
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.